30 Mar
by Vitaliy Dadalyan
J&J also committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, expanding a previous collaboration. A patient was dosed with Moderna Inc’s vaccine in an early-stage trial earlier this month, making it the front-runner in the race to develop a viable vaccine. J&J said in January it had begun working on a possible vaccine for the coronavirus, using the same technologies used to make its experimental Ebola vaccine.
